Skip to content

Effect of rTMS device in improving walking in patients with Parkinson's disease

Effect of Repetitive Transcranial Magnetic Stimulation over the supplementary motor area and dorsolateral prefrontal cortex in improvement of gait in Parkinson’s disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230125057225N1
Enrollment
21
Registered
2023-02-01
Start date
2023-02-09
Completion date
Unknown
Last updated
2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease. Parkinson's disease

Interventions

Intervention 1: Intervention group:The intervention is by rTMS device made by Madinatab Iran company and the evaluation is done by three dimensional motion analysis device and by Qualysis software and

Sponsors

Semnan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with advanced Parkinson's (patients who are in advanced stages often have movement problems - incontinence - insomnia and dementia) People with Parkinson's disease have freezing of gait (FOG). People with Parkinson's who take L-Dopa People who are over 45 years old (according to the opinion of the neurologist who advised the article) The patient should be able to walk without crutches

Exclusion criteria

Exclusion criteria: Associated painful conditions that may distort the clinical picture of the study People who have a history of epilepsy and have a history of taking antiepileptic drugs such as benzodiazepines. People with a history of cerebral hemorrhage People who have problems such as brain aneurysm or brain plaque People with dementia Based on the Bech questionnaire, patients with major depression are excluded from the study

Design outcomes

Primary

MeasureTime frame
1- The variable of hip-knee-ankle joint movement angles which is measured by the motion device. Timepoint: Before starting the intervention - the end of 10 treatment sessions -1month follow-up. Method of measurement: three dimensional motion analysis device.;The variable of the movement score which is measured by the UPDRS-part 3 questionnaire. Timepoint: Before starting the intervention - the end of 10 treatment sessions -1month follow-up. Method of measurement: Questionnaire UPDRS-part 3.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Heidarinejad

Semnan University of Medical Sciences

aliheidarinejad7444@gmail.com+98 21 4494 4265

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026